Alps Advisors Inc Aprea Therapeutics, Inc. Transaction History

Alps Advisors Inc

$14.8 Billion
Q3 2024

Shares

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2021 Aug 11, 2021	SELL	$4.05 - $5.5 $155,232 - $210,809	-38,329 Closed	0 $0
Q1 2021 May 07, 2021	BUY	$4.73 - $8.15 $165 - $285	35 Added 0.09%	38,329 $195,000
Q4 2020 Feb 03, 2021	BUY	$4.92 - $30.67 $55,502 - $345,988	11,281 Added 41.76%	38,294 $188,000
Q3 2020 Nov 04, 2020	SELL	$21.66 - $38.86 $37,081 - $66,528	-1,712 Reduced 5.96%	27,013 $650,000
Q2 2020 Aug 05, 2020	SELL	$25.47 - $39.69 $240,334 - $374,514	-9,436 Reduced 24.73%	28,725 $1.11 Million
Q1 2020 May 06, 2020	SELL	$31.65 - $45.3 $140,874 - $201,630	-4,451 Reduced 10.45%	38,161 $1.33 Million
Q4 2019 Feb 07, 2020	BUY	$18.94 - $49.53 $807,071 - $2.11 Million	42,612 New	42,612 $1.96 Million

Others Institutions Holding APRE

# of Institutions

2

Shares Held

899

Call Options Held

0

Put Options Held

0

Nbc Securities, Inc. Birmingham, AL

899
Shares

$2,688
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.